IBM and Illumina Partner on Work to Standardize Genomic Data Interpretation | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

IBM and Illumina Partner on Work to Standardize Genomic Data Interpretation

January 10, 2017
by Heather Landi
| Reprints

IBM Watson Health and Illumina, Inc., a DNA sequencing and array-based technologies company, are partnering with the aim of helping cancer genomics researchers interpret the results of sequences.

As part of the partnership, IBM will integrate Watson for Genomics into Illumina’s BaseSpace Sequence Hub and tumor sequencing process. The collaboration is designed to help standardize and simplify genomic data interpretation. Genome sequencing has increased in recent years following two decades of research demonstrating the promise of precision medicine. However, access to these advances has been limited by the significant time and expense required to interpret the genomic data.

According to an IBM press release, by adding Watson for Genomics to Illumina’s next-generation sequencing platform, researchers who use Illumina’s cancer genome sequencing panel will have rapid access to information to help interpret the broad array of variant data produced by TruSight Tumor 170.  Illumina’s TruSight Tumor 170 is a solid tumor profiling panel designed to detect a comprehensive set of variants across 170 genes.

Through the technology integration, Watson for Genomics will read the genetic alteration files produced by TruSight Tumor 170, comb professional guidelines, medical literature, clinical trials compendia, and other sources of knowledge to provide information for each genomic alteration, and produce a report for use by researchers—a process that typically takes scientists more than one week to complete. Watson for Genomics ingests data from approximately 10,000 scientific articles and 100 new clinical trials every month.

The Watson for Genomics software will be available to support Illumina’s TruSight Tumor 170 assay early in 2017. The Watson service is not yet available for diagnostic use and is for research use only.

 

 

Get the latest information on Healthcare Analytics and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More

Topics

News

Health Sciences South Carolina Wins ‘Best in Show’ at FHIR Applications Roundtable

At the HL7 FHIR Applications Roundtable held in New Orleans in December, Health Sciences South Carolina (HSSC) was voted Best in Show for its clinical data repository for South Carolina hospitals.

2018 Most Influential Women in Health IT Awardees Announced

Four healthcare IT leaders—Ann O’Brien, R.N., Judy Murphy, R.N., Jessica Kahn and Vice Admiral Raquel C. Bono—have been named as the 2018 awardees of HIMSS’ Most Influential Women in Health IT.

Reports: DoD-Cerner EHR Rollout Postponed for 8 Weeks

The Department of Defense (DoD) and Cerner are suspending their MHS Genesis electronic health record (EHR) modernization project for eight weeks, according to multiple media reports.

Change Healthcare Announces Availability of Enterprise-Scale Blockchain Solution

Executives from Nashville-based Change Healthcare have announced that its Intelligent Healthcare Network with blockchain is now available featuring claims management transparency, attesting that it is the first enterprise-scale blockchain in healthcare.

Health IT Experts Join Health Catalyst Team

Salt Lake City-based healthcare data analytics company Health Catalyst has added three health IT and quality heavyweights as strategic advisors.

Rock Health: Digital Health Venture Funding Reached $5.8B in 2017

Digital health venture funding in 2017 approached $6 billion and had the most mega deals ($100 million+) to date, according to a year-end report from San Francisco-based Rock Health.